国际儿科学杂志
國際兒科學雜誌
국제인과학잡지
INTERNATIONAL JOURNAL OF PEDIATRICS
2010年
2期
142-144,185
,共4页
磷酸二酯酶5抑制剂%肺动脉高压%先天性心脏病
燐痠二酯酶5抑製劑%肺動脈高壓%先天性心髒病
린산이지매5억제제%폐동맥고압%선천성심장병
Phosphodiesterase 5 inhibitors%Pulmonary arterial hypertension%Congenital heart disease
肺动脉高压在先天性心脏病中很常见,有效地降低患儿肺血管阻力,能够改善其远期生存率.对肺动脉高压病理生理的研究发现,使用磷酸二酯酶5抑制剂可使肺血管舒张,降低肺血管阻力.目前磷酸二酯酶5抑制剂西地那非在国外已用于治疗肺动脉高压.多个临床试验已经证明磷酸二酯酶5抑制剂能够显著降低肺血管阻力,改善患者远期生存率和生活质量,且能较好地被患者耐受.
肺動脈高壓在先天性心髒病中很常見,有效地降低患兒肺血管阻力,能夠改善其遠期生存率.對肺動脈高壓病理生理的研究髮現,使用燐痠二酯酶5抑製劑可使肺血管舒張,降低肺血管阻力.目前燐痠二酯酶5抑製劑西地那非在國外已用于治療肺動脈高壓.多箇臨床試驗已經證明燐痠二酯酶5抑製劑能夠顯著降低肺血管阻力,改善患者遠期生存率和生活質量,且能較好地被患者耐受.
폐동맥고압재선천성심장병중흔상견,유효지강저환인폐혈관조력,능구개선기원기생존솔.대폐동맥고압병리생리적연구발현,사용린산이지매5억제제가사폐혈관서장,강저폐혈관조력.목전린산이지매5억제제서지나비재국외이용우치료폐동맥고압.다개림상시험이경증명린산이지매5억제제능구현저강저폐혈관조력,개선환자원기생존솔화생활질량,차능교호지피환자내수.
Pulmonary arterial hypertension is common in patients with congenital heart disease.An effective reduction in pulmonary vascular resistance could improve the survival rate in the future.Research in the pathophysiology of pulmonary arterial hypertension shows that phosphodiesterase 5 inhibitors result in pulmonary vasodilation,decrease vascular resistance.Sildenafil,a inhibitor of phosphodiesterase 5 has been permitted to treat pulmonary arterial hypertension oversea now.Phosphodiesterase 5 inhibitors are proved to reduce pulmonary vascular resistance significantly,improve the survival rate in the future and be well tolerated.This review contains the changes of hemodynamics,exercise tolerance,side effect and pharmacokinetics of phosphodiesterase 5 inhibitors.
